You are here

Article Text

Article menu
Download PDFPDF
Letters to the editor
Inhaled corticosteroids and mortality in COPD: are we there yet?
  1. R Stirling
  1. Monash University, Department of Allergy Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Victoria 3004, Australia;r.stirling@alfred.org.au

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A broader indication for inhaled corticosteroids (ICS) in COPD has been sought for some time. The recent meta-analysis by Sin et al1 suggesting protection against all-cause mortality is therefore of some interest. Although not universally confirmed,2,3 this tantalising concept is being prospectively evaluated in a 3 year study of high dose ICS (fluticasone …

    View Full Text